In order to test our hypothesis that blocking this pathway could improve leukemia outcome, we used TAE226, the inhibitor of FAK, an integrin downstream factor, in combination with the TKI, nilotinib, to determine whether they would synergize. The gene discussed is PTK2; the disease is leukemia.